AMLX
Amylyx Pharmaceuticals, Inc.
$13.01
-2.33%
$1.5B
No data for this timeframe.
Vol
Market Cap$1.5B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders8 funds
Inst. Value$331.2M
Inst. Activity5 buys / 0 sells
Insider Activity1B / 10S
Insider Net $-$1.7M
SEC Reports3
Recent Activity
Apr 13, 2027
fda_pdufa
PDUFA: AMLX — avexitide in post-bariatric hypoglycemia — 2027-04-13
FDA target action date 2027-04-13 for AMLX (Amylyx Pharmaceuticals, Inc.). Drug: avexitide. Indicati
Jun 4, 2026
Insider
Firestone Karen sold 24,372 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
FONTEYNE PAUL R. sold 24,372 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
MILNE GEORGE M JR sold 24,372 shares
Director @ $0.00 ($0.00)
Apr 23, 2026
SEC
Amylyx Pharmaceuticals is holding its 2026 annual shareholder meeting to vote on director elections, auditor ratificatio
DEFA14A — Impact 3/10
Mar 9, 2026
SEC
Seven executives at Amylyx Pharmaceuticals, including both Co-CEOs, the CFO, CMO, and Chief Legal Officer, were awarded
CLUSTER — Impact 3/10
Mar 4, 2026
SEC
Five senior executives at Amylyx Pharmaceuticals, including both Co-CEOs, the CFO, CMO, and Chief Legal Officer, collect
CLUSTER — Impact 7/10
Inst.
FMR LLC — ADD
16,518,419 shares ($199.5M)
Price Targets
$23.40
+72.7% upside
Strong Buy
Current $13.55
Low $19.00
Median $21.50
High $34.00
10 analysts
$19.00
$34.00
Analyst Ratings
8Strong Buy
8Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 28, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Mar 25, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 19, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 3, 2026 | Stifel | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.35 ▲ +1.8% | $-0.41 — $-0.26 | 24% YoY | 8 |
| Next Q | $-0.33 ▲ +1.5% | $-0.40 — $-0.23 | 10% YoY | 8 |
| Current FY | $-1.38 ▲ +1.4% | $-1.59 — $-1.05 | 10% YoY | 8 |
| Next FY | $-1.27 ▼ -3.3% | $-1.71 — $-0.54 | 9% YoY | 8 |
Latest Reports
NEUTRAL
DEFA14A
3/10
Amylyx Pharmaceuticals is holding its 2026 annual shareholder meeting to vote on director elections, auditor ratificatio
Apr 23, 2026
NEUTRAL
CLUSTER
3/10
Seven executives at Amylyx Pharmaceuticals, including both Co-CEOs, the CFO, CMO, and Chief Legal Officer, were awarded
Mar 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $199.5M | ADD |
| VANGUARD GROUP INC | $70.1M | ADD |
| MORGAN STANLEY | $28.5M | DOUBLED |
| BANK OF AMERICA CORP | $16.1M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $8.6M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Firestone Karen | A | $0.00 |
| Jun 4, 2026 | FONTEYNE PAUL | A | $0.00 |
| Jun 4, 2026 | MILNE GEORGE | A | $0.00 |
| Jun 4, 2026 | Zeiher Bernhardt | A | $0.00 |
| Jun 4, 2026 | Quimi Daphne | A | $0.00 |
8 institutional holders with $331.2M total value (27,415,365 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, MORGAN. Net buying activity: 5 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 16,518,419 | $199.5M | 60.3% | ADD +45.2% |
| 2 | VANGUARD GROUP INC | 5,804,912 | $70.1M | 21.2% | ADD +52.9% |
| 3 | MORGAN STANLEY | 2,359,824 | $28.5M | 8.6% | DOUBLED +300.6% |
| 4 | BANK OF AMERICA CORP /DE/ | 1,336,010 | $16.1M | 4.9% | DOUBLED +211.1% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 712,990 | $8.6M | 2.6% | ADD +57.8% |
| 6 | TWO SIGMA INVESTMENTS, LP | 344,401 | $4.2M | 1.3% | DOUBLED +249.9% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 192,500 | $2.3M | 0.7% | DOUBLED +867.3% |
| 8 | WELLS FARGO & COMPANY/MN | 146,309 | $1.8M | 0.5% | ADD +56.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 11,379,207 | 16,518,419 | +45.2% | $199.5M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 429,516 | 1,336,010 | +211.1% | $16.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 98,416 | 344,401 | +249.9% | $4.2M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 19,900 | 192,500 | +867.3% | $2.3M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 93,691 | 146,309 | +56.2% | $1.8M | 2025-Q4 |
| FMR LLC | DOUBLED | 3,048,019 | 11,379,207 | +273.3% | $154.6M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 486,893 | 1,950,301 | +300.6% | $26.5M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 558,846 | 98,416 | -82.4% | $1.3M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 38,101 | 93,691 | +145.9% | $1.3M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 396,200 | 19,900 | -95.0% | $270.4K | 2025-Q3 |
| FMR LLC | DOUBLED | 1,157,988 | 3,048,019 | +163.2% | $19.5M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 372,853 | 588,411 | +57.8% | $3.8M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 762,053 | 558,846 | -26.7% | $3.6M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 794,354 | 451,808 | -43.1% | $2.9M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 300 | 38,101 | +12600.3% | $244.2K | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 2,692,489 | 4,116,512 | +52.9% | $14.6M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 2,230,304 | 2,820,876 | +26.5% | $10.0M | 2025-Q1 |
| UBS Group AG | DOUBLED | 643,524 | 1,388,427 | +115.8% | $4.9M | 2025-Q1 |
| FMR LLC | ADD | 731,356 | 1,157,988 | +58.3% | $4.1M | 2025-Q1 |
| UBS Group AG | DOUBLED | 229,076 | 643,524 | +180.9% | $2.4M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 271,800 | 464,400 | +70.9% | $1.8M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 924,459 | 478,265 | -48.3% | $1.5M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 302,270 | — | $979.4K | 2024-Q3 |
10 unique insiders with 11 transactions. Net insider value: -$1.7M ($51.3K bought, $1.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Firestone Karen | Director | A | 24,372 | $0.00 | $0.00 |
| Jun 4, 2026 | FONTEYNE PAUL R. | Director | A | 24,372 | $0.00 | $0.00 |
| Jun 4, 2026 | MILNE GEORGE M JR | Director | A | 24,372 | $0.00 | $0.00 |
| Jun 4, 2026 | Zeiher Bernhardt G | Director | A | 24,372 | $0.00 | $0.00 |
| Jun 4, 2026 | Quimi Daphne | Director | A | 24,372 | $0.00 | $0.00 |
| May 21, 2026 | Firestone Karen | Director | BUY | 3,800 | $13.51 | $51.3K |
| Mar 5, 2026 | Bedrosian Camille L | Chief Medical Officer | A | 95,990 | $0.00 | $0.00 |
| Mar 5, 2026 | Mazzariello Gina | Chief Legal Officer | A | 74,660 | $0.00 | $0.00 |
| Mar 5, 2026 | Cohen Joshua B | Co-Chief Executive Officer | A | 248,865 | $0.00 | $0.00 |
| Mar 5, 2026 | FRATES JAMES M | Chief Financial Officer | A | 143,985 | $0.00 | $0.00 |
| Mar 5, 2026 | Bedrosian Camille L | Chief Medical Officer | A | 143,985 | $0.00 | $0.00 |
| Mar 5, 2026 | Mazzariello Gina | Chief Legal Officer | A | 111,990 | $0.00 | $0.00 |
| Mar 5, 2026 | Klee Justin B. | Co-Chief Executive Officer | A | 248,865 | $0.00 | $0.00 |
| Mar 5, 2026 | Cohen Joshua B | Co-Chief Executive Officer | A | 373,295 | $0.00 | $0.00 |
| Mar 5, 2026 | FRATES JAMES M | Chief Financial Officer | A | 95,990 | $0.00 | $0.00 |
| Mar 5, 2026 | Klee Justin B. | Co-Chief Executive Officer | A | 373,295 | $0.00 | $0.00 |
| Mar 2, 2026 | Mazzariello Gina | Chief Legal Officer | SELL | 6,844 | $14.52 | $99.4K |
| Mar 2, 2026 | FRATES JAMES M | Chief Financial Officer | SELL | 7,909 | $14.52 | $114.9K |
| Mar 2, 2026 | Cohen Joshua B | Co-Chief Executive Officer | SELL | 29,282 | $14.48 | $424.1K |
| Mar 2, 2026 | Bedrosian Camille L | Chief Medical Officer | SELL | 6,461 | $14.58 | $94.2K |
| Mar 2, 2026 | Klee Justin B. | Co-Chief Executive Officer | SELL | 29,282 | $14.47 | $423.8K |
| Feb 23, 2026 | Mazzariello Gina | Chief Legal Officer | SELL | 3,419 | $14.14 | $48.4K |
| Feb 2, 2026 | Klee Justin B. | Co-Chief Executive Officer | SELL | 15,500 | $14.69 | $227.6K |
| Feb 2, 2026 | Mazzariello Gina | Chief Legal Officer | SELL | 3,448 | $14.65 | $50.5K |
| Feb 2, 2026 | FRATES JAMES M | Chief Financial Officer | SELL | 3,557 | $14.65 | $52.1K |
| Feb 2, 2026 | Cohen Joshua B | Co-Chief Executive Officer | SELL | 15,500 | $14.68 | $227.6K |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
DEFA14A
3/10
Amylyx Pharmaceuticals is holding its 2026 annual shareholder meeting to vote on director elections,
Apr 23, 2026
NEUTRAL
CLUSTER
3/10
Seven executives at Amylyx Pharmaceuticals, including both Co-CEOs, the CFO, CMO, and Chief Legal Of
Mar 9, 2026
BEARISH
CLUSTER
7/10
Five senior executives at Amylyx Pharmaceuticals, including both Co-CEOs, the CFO, CMO, and Chief Le
Mar 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (89% buy). Based on 18 analysts: 8 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$23.40 mean target
+72.7% upside
Strong Buy (1.17)
$19.00 Low
$34.00 High
| Metric | Value |
|---|---|
| Current Price | $13.55 |
| Target Low | $19.00 |
| Target Mean | $23.40 |
| Target Median | $21.50 |
| Target High | $34.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.17) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.35 | $-0.41 | $-0.26 | 24.4% | +1.8% | 2↑ 2↓ | $0.0B | 0.0% | 8 |
| Next Q 2026-09-30 |
$-0.33 | $-0.40 | $-0.23 | 9.6% | +1.5% | 2↑ 2↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-1.38 | $-1.59 | $-1.05 | 9.5% | +1.4% | 3↑ 4↓ | $0.0B | 0.0% | 8 |
| Next FY 2027-12-31 |
$-1.27 | $-1.71 | $-0.54 | 8.6% | -3.3% | 3↑ 4↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.348 | |
| 7d ago | $-0.348 | |
| 30d ago | $-0.354 | +0.006 |
| 60d ago | $-0.351 | +0.003 |
| 90d ago | $-0.351 | +0.003 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 28, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 25, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 19, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | Stifel | INITIATE | — | Buy |
| Feb 20, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 8 | 2 | 0 | 0 | 89% | |
| May 1, 2026 | 8 | 8 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 8 | 8 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 13, 2027
fda_pdufa
PDUFA: AMLX — avexitide in post-bariatric hypoglycemia — 2027-04-13
FDA target action date 2027-04-13 for AMLX (Amylyx Pharmaceuticals, Inc.). Drug: avexitide. Indication: post-bariatric hypoglycemia. PDUFA target acti
Jun 5, 2026
short_volume
Short Volume: AMLX — 55.6% short (0.4M / 0.8M)
Short: 447,735 | Exempt: 5,070 | TRF Vol: 805,128 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: AMLX — 72.4% short (0.5M / 0.7M)
Short: 533,918 | Exempt: 0 | TRF Vol: 737,123 | Short Ratio: 72.4% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: AMLX — 75.7% short (0.4M / 0.6M)
Short: 438,063 | Exempt: 0 | TRF Vol: 578,659 | Short Ratio: 75.7% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
AMLX Q1 2026 Earnings Scheduled — 2026-05-07
May 7, 2026
short_volume
Short Volume: AMLX — 68.9% short (0.4M / 0.5M)
Short: 362,800 | Exempt: 656 | TRF Vol: 526,921 | Short Ratio: 68.9% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: AMLX — 60.9% short (0.4M / 0.6M)
Short: 369,630 | Exempt: 0 | TRF Vol: 606,638 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
Clinical Trial
AMX0035 and Progressive Supranuclear Palsy
Phase Phase 3 — COMPLETED
Apr 17, 2026
short_volume
Short Volume: AMLX — 57.1% short (0.4M / 0.6M)
Short: 370,134 | Exempt: 6,802 | TRF Vol: 647,905 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
short_volume
Short Volume: AMLX — 70.8% short (0.4M / 0.5M)
Short: 368,791 | Exempt: 0 | TRF Vol: 520,882 | Short Ratio: 70.8% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
short_interest
FTD: AMLX — 89,736 shares ($1.2M) failed to deliver
Settlement: 20260324, Price: $13.53, FTD Value: $1,214,128.08, AMYLYX PHARMACEUTICALS INC COM
Mar 3, 2026
earnings_calendar
AMLX Q4 2025 Earnings After Market Close — 2026-03-03
Mar 3, 2026
short_interest
FTD: AMLX — 174,107 shares ($2.7M) failed to deliver
Settlement: 20260303, Price: $15.30, FTD Value: $2,663,837.1, AMYLYX PHARMACEUTICALS INC COM
Mar 2, 2026
earnings_calendar
AMLX Q4 2025 Earnings After Market Close — 2026-03-02